Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Given Buy Rating at HC Wainwright

Posted by Jessica Moore on May 9th, 2024

HC Wainwright reiterated their buy rating on shares of Armata Pharmaceuticals (NYSEAMERICAN:ARMP – Free Report) in a research note published on Wednesday morning, Benzinga reports. The firm currently has a $7.00 target price on the stock.

Armata Pharmaceuticals Price Performance

Shares of Armata Pharmaceuticals stock opened at $2.91 on Wednesday. Armata Pharmaceuticals has a 1 year low of $1.07 and a 1 year high of $5.26. The firm has a market cap of $105.20 million, a price-to-earnings ratio of -1.40 and a beta of 0.96.

Armata Pharmaceuticals (NYSEAMERICAN:ARMP – Get Free Report) last posted its earnings results on Thursday, March 21st. The company reported ($0.55) EPS for the quarter. Armata Pharmaceuticals had a negative net margin of 1,524.51% and a negative return on equity of 280.95%. The firm had revenue of $1.53 million during the quarter, compared to analyst estimates of $0.68 million. On average, sell-side analysts forecast that Armata Pharmaceuticals will post -1.34 EPS for the current fiscal year.

Institutional Trading of Armata Pharmaceuticals

A hedge fund recently raised its stake in Armata Pharmaceuticals stock. SeaCrest Wealth Management LLC increased its holdings in Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP – Free Report) by 80.8% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 32,777 shares of the company’s stock after purchasing an additional 14,647 shares during the quarter. SeaCrest Wealth Management LLC owned approximately 0.09% of Armata Pharmaceuticals worth $137,000 at the end of the most recent reporting period. 3.57% of the stock is currently owned by institutional investors.

About Armata Pharmaceuticals

(Get Free Report)

Armata Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia.